{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:07Z","timestamp":1788419767046,"version":"build-2803163510"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic hepatitis B (CHB) remains a significant global public health challenge. The goals of its antiviral therapy are gradually shifting from long-term viral suppression toward achieving safer treatment discontinuation, more accurate risk stratification, and deeper functional cure. Traditional serological markers, such as HBV DNA and HBsAg, remain clinically important in CHB. However, their ability to reflect residual viral activity and long-term outcomes is limited after long-term nucleos(t)ide analog (NA) therapy, especially in patients with sustained virological suppression or marked HBsAg decline or clearance.In recent years, hepatitis B core-related antigen (HBcrAg), due to its capacity to reflect transcriptional activity of intrahepatic covalently closed circular DNA(cccDNA) and the state of the residual viral reservoir, has emerged as a notable novel biomarker in the field of CHB. Concurrently, with the development of pegylated interferon (Peg-IFN) add-on strategies and novel combination cure approaches, the potential of HBcrAg in selecting optimal patient populations and monitoring therapeutic efficacy is increasingly recognized. This review focuses on the biological basis of HBcrAg and its main predictive values in CHB antiviral therapy. It also summarizes and prospects its clinical application potential and existing challenges based on current research progress.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1893489","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:20Z","timestamp":1788417800000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of serum HBcrAg in antiviral therapy for chronic hepatitis B"],"prefix":"10.3389","volume":"17","author":[{"given":"Shiyu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0780","article-title":"Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0","volume":"31","author":"Wu","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.02.017","article-title":"Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation","volume":"75","author":"Inoue","year":"2021","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2025.00064","article-title":"Emerging serum biomarkers for chronic hepatitis B: Focus on serum HBV RNA and HBcrAg","volume":"13","author":"Tian","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1083912","article-title":"Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.189904","article-title":"HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon alfa-2b","volume":"129","author":"Ma","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada","year":"2016","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.017","article-title":"A critique and systematic review of the clinical utility of hepatitis B core-related antigen","volume":"78","author":"Adraneda","year":"2023","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus. core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J Clin Microbiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0434","article-title":"Hepatitis B core-related antigen: A novel and promising. surrogate biomarker to guide anti-hepatitis B virus therapy","volume":"29","author":"Inoue","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17105","article-title":"Review article: novel biomarkers in hepatitis B infection","volume":"56","author":"Lok","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324646","article-title":"Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection","volume":"71","author":"Aliabadi","year":"2022","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.07.027","article-title":"Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients","volume":"486","author":"Chen","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv572","article-title":"Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma","volume":"213","author":"Honda","year":"2016","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v13020180","article-title":"Hepatitis B virus DNA integration: In vitro models for investigating viral pathogenesis and persistence","volume":"13","author":"Tu","year":"2021","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0420","article-title":"Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm","volume":"29","author":"Hsu","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16029","article-title":"High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy","volume":"44","author":"Hume","year":"2024","journal-title":"Liver Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2022.06.002","article-title":"End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients","volume":"56","author":"Brakenhoff","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac409","article-title":"Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation","volume":"78","author":"Tseng","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/v16040529","article-title":"Quantitative measurement of serum HBcrAg can be used to assess the feasibility of safe discontinuation of antiviral therapy for chronic hepatitis B","volume":"16","author":"Wang","year":"2024","journal-title":"Viruses"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S321253","article-title":"Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B","volume":"14","author":"Liao","year":"2021","journal-title":"Int J Gen Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.436","article-title":"Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"Matsumoto","year":"2007","journal-title":"Hepatol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Shinkai","year":"2016","journal-title":"J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2006.08.005","article-title":"Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection","volume":"36","author":"Jung","year":"2006","journal-title":"Hepatol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hepr.12269","article-title":"JSH guidelines for the management of hepatitis B virus infection","year":"2014","journal-title":"Hepatol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"Chuaypen","year":"2016","journal-title":"Liver Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13097","article-title":"Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues","volume":"26","author":"Sonneveld","year":"2019","journal-title":"J Viral Hepat"},{"key":"B37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jvh.13765","article-title":"Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals","volume":"30","author":"Hwang","year":"2023","journal-title":"J Viral Hepat"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3367","article-title":"Hepatitis B core-related antigen levels predict pegylated interferon-\u03b1 therapy response in HBeAg-positive chronic hepatitis B","volume":"25","author":"Beudeker","year":"2020","journal-title":"Antivir Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"Tada","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100956","article-title":"HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative","volume":"6","author":"Hosaka","year":"2023","journal-title":"JHEP Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28210","article-title":"Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B","volume":"95","author":"Tseng","year":"2023","journal-title":"J Med Virol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep4.1819","article-title":"Ultrasensitive assay for hepatitis B core-related antigen predicts hepatocellular carcinoma incidences during entecavir","volume":"6","author":"Kaneko","year":"2022","journal-title":"Hepatol Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4456","article-title":"Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"28","author":"Yang","year":"2010","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13602","article-title":"Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"51","author":"Suzuki","year":"2021","journal-title":"Hepatol Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12072-012-9354-7","article-title":"Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay","volume":"7","author":"Seto","year":"2012","journal-title":"Hepatol Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2022.105375","article-title":"A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays","volume":"160","author":"Wong","year":"2023","journal-title":"J Clin Virol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2025.100617","article-title":"Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study","volume":"11","author":"Wang","year":"2025","journal-title":"J Virus Erad"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/v16060848","article-title":"Two concepts of hepatitis B core-related antigen assay: A highly sensitive and rapid assay or an effective tool for widespread screening","volume":"16","author":"Inoue","year":"2024","journal-title":"Viruses"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13489","article-title":"Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS)","volume":"28","author":"Shimakawa","year":"2021","journal-title":"J Viral Hepat"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J Hepatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J Viral Hepat"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i1.98658","article-title":"Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure","volume":"17","author":"Qiu","year":"2025","journal-title":"World J Hepatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100720","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae541","article-title":"Hepatitis B Virus RNA as a biomarker for safe antiviral discontinuation: A prospective study of nucleos(t)ide analogue withdrawal","volume":"231","author":"Terrault","year":"2025","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg \u2009<\u2009100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J Gastroenterol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332290","article-title":"HBcrAg values may predict virological and immunological responses to pegIFN-\u03b1 in NUC-suppressed HBeAg-negative chronic hepatitis B","volume":"73","author":"Vecchi","year":"2024","journal-title":"Gut"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in north america","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis","volume":"53","author":"Brunetto","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106601","article-title":"Evaluation of Hepatitis B core-related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa","volume":"91","author":"Downs","year":"2025","journal-title":"J Infect"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae241","article-title":"Profiles of HBcrAg and pgRNA in pregnant women with chronic HBV under different disease phases and antiviral prophylaxis","volume":"11","author":"Wang","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1511855","article-title":"PgRNA closely correlates to cytokine profile in HBeAg-positive pregnant women undergoing prophylactic antiviral intervention","volume":"15","author":"Tang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:21Z","timestamp":1788417801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1893489"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1893489","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1893489"}}